Major US consumer group asks FDA to ban drug for diabetes.
作者信息
Tanne Janice Hopkins
出版信息
BMJ. 2008 Nov 5;337:a2401. doi: 10.1136/bmj.a2401.
PMID:18987042
Abstract
摘要
相似文献
1
Major US consumer group asks FDA to ban drug for diabetes.
BMJ. 2008 Nov 5;337:a2401. doi: 10.1136/bmj.a2401.
2
Commentary: What can we learn from the continuing regulatory focus on the thiazolidinediones?
BMJ. 2010 Sep 6;341:c4812. doi: 10.1136/bmj.c4812.
3
Rosiglitazone: what went wrong?
BMJ. 2010 Sep 6;341:c4848. doi: 10.1136/bmj.c4848.
4
Avandia panel member may be investigated for possible conflicts of interest.
BMJ. 2010 Aug 3;341:c4083. doi: 10.1136/bmj.c4083.
5
FDA places greater restrictions on access to rosiglitazone.
BMJ. 2010 Sep 24;341:c5287. doi: 10.1136/bmj.c5287.
6
FDA committees say keep rosiglitazone available but increase warnings.
BMJ. 2007 Aug 4;335(7613):223. doi: 10.1136/bmj.39294.417442.DB.
7
Licensing drugs for diabetes.
BMJ. 2010 Sep 6;341:c4805. doi: 10.1136/bmj.c4805.
8
Anticipated US approval for rosiglitazone and pioglitazone.
Diabetes Obes Metab. 1999 May;1(3):181-2.
9
FDA puts restrictions on use of controversial diabetes drug.
Mayo Clin Womens Healthsource. 2011 Feb;15(2):3.
10
FDA committee urges tight restrictions on rosiglitazone.
BMJ. 2010 Jul 16;341:c3862. doi: 10.1136/bmj.c3862.
Zotero 插件